Cargando…

Temozolomide chronotherapy in patients with glioblastoma: a retrospective single-institute study

BACKGROUND: Chronotherapy is an innovative approach to improving survival through timed delivery of anti-cancer treatments according to patient daily rhythms. Temozolomide (TMZ) is a standard-of-care chemotherapeutic agent for glioblastoma (GBM). Whether timing of TMZ administration affects GBM pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Damato, Anna R, Luo, Jingqin, Katumba, Ruth G N, Talcott, Grayson R, Rubin, Joshua B, Herzog, Erik D, Campian, Jian L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086242/ https://www.ncbi.nlm.nih.gov/pubmed/33959716 http://dx.doi.org/10.1093/noajnl/vdab041

Ejemplares similares

Temozolomide Chronotherapy in Glioma: A Systematic Review
por: Jia, Jason L., et al.
Publicado: (2023)

The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma
por: Xi, Jing, et al.
Publicado: (2021)

Chronotherapy in Glioblastoma: State of the art and future perspectives
por: Petković, Marina, et al.
Publicado: (2023)

A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma
por: Butt, Omar H, et al.
Publicado: (2021)

Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide
por: Sun, Stella, et al.
Publicado: (2012)

On optimal temozolomide scheduling for slowly growing glioblastomas
por: Segura-Collar, Berta, et al.
Publicado: (2022)

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
por: Vieito, Maria, et al.
Publicado: (2022)

Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
por: Faye, Mame Daro, et al.
Publicado: (2023)

NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma
por: Sim, Hao-Wen, et al.
Publicado: (2023)

Implantable system for chronotherapy
por: Lee, Seung Ho, et al.
Publicado: (2021)

Phase I trial of dimethyl fumarate, temozolomide, and radiation therapy in glioblastoma
por: Shafer, Danielle, et al.
Publicado: (2020)

Resistant Hypertension and Chronotherapy
por: Prkacin, Ingrid, et al.
Publicado: (2015)

Chronobiology and Chronotherapy of Osteoporosis
por: Winter, Elizabeth M, et al.
Publicado: (2021)

Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1
por: Gallitto, Matthew, et al.
Publicado: (2020)

Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825
por: Scheurer, Michael E, et al.
Publicado: (2022)

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
por: Van Den Bent, Martin, et al.
Publicado: (2020)

Glucocorticoids and chronotherapy in rheumatoid arthritis
por: Cutolo, Maurizio
Publicado: (2016)

Chronotherapy with defective circadian clock?
por: Zhang, Yuan, et al.
Publicado: (2018)

Chronotherapy Network Netherlands (CNN)
por: Meesters, Ybe, et al.
Publicado: (2019)

Chronotherapy in COVID-19 Disease
por: LACOUT, Alexis, et al.
Publicado: (2021)

New Insights Into Cancer Chronotherapies
por: Zhou, Jingxuan, et al.
Publicado: (2021)

The Time for Chronotherapy in Radiation Oncology
por: Bermúdez-Guzmán, Luis, et al.
Publicado: (2021)

A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study
por: Sim, Hao-Wen, et al.
Publicado: (2021)

Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial
por: Hanna, Catherine, et al.
Publicado: (2020)

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
por: Lim, Michael, et al.
Publicado: (2022)

A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia
por: Musah-Eroje, Ahmed, et al.
Publicado: (2019)

Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma
por: Weathers, Shiao-Pei, et al.
Publicado: (2021)

Chronobiology and Chronotherapy in Inflammatory Joint Diseases
por: Ursini, Francesco, et al.
Publicado: (2021)

Embedding digital chronotherapy into bioelectronic medicines
por: Fleming, John E., et al.
Publicado: (2022)

Cannabidiol inhibits RAD51 and sensitizes glioblastoma to temozolomide in multiple orthotopic tumor models
por: Soroceanu, Liliana, et al.
Publicado: (2022)

Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma
por: Daniel, Paul, et al.
Publicado: (2022)

Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines
por: Sun, Stella, et al.
Publicado: (2011)

Development of Aplastic Anemia during Treatment of Anaplastic Astrocytoma with Temozolomide
por: Khaddour, Karam, et al.
Publicado: (2020)

Multivariate analysis of associations between clinical sequencing and outcome in glioblastoma
por: Yang, Peter H, et al.
Publicado: (2022)

Radiotherapy plus Concomitant Adjuvant Temozolomide for Glioblastoma: Japanese Mono-Institutional Results
por: Oike, Takahiro, et al.
Publicado: (2013)

Prolonged response of recurrent IDH-wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab
por: Hwang, Helen, et al.
Publicado: (2022)

A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma
por: Werlenius, Katja, et al.
Publicado: (2021)

Extent of MGMT promoter methylation modifies the effect of temozolomide on overall survival in patients with glioblastoma: a regional cohort study
por: Poon, Michael T C, et al.
Publicado: (2021)

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
por: Omuro, Antonio, et al.
Publicado: (2022)

Chronotherapy: Intuitive, Sound, Founded…But Not Broadly Applied
por: Selfridge, Julia M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_he7f5dv5p0357is4m8d86ejd62